Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of JM-010 in Parkinson's Disease Patients With Dyskinesia
2022-002818-16Phase 2Completed
- Sponsor
- Contera Pharma
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JM-010 in Parkinson's disease (PD), sponsored by Contera Pharma. Primary endpoint: Safety and tolerability of JM-010 from Baseline to Week 48. Started Nov 2022; status: completed.
02
Drugs
JM-010
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2022-002818-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002818-16.